All In MedTech

FDA Clearance Tracker · P250008

Claire™ OCT System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Mar 3, 2026

Approved

Time to decision

355 days

Received Mar 13, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P250008
Device name
Claire™ OCT System
Applicant location
Toronto
Received
Mar 13, 2025
Decided
Mar 3, 2026
Decision
Approved
Supplements
1 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code SHH

FDA's approval statement

As written in FDA's record.

The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SHH (OCT imaging system with AI/ML software for adjunctive detection of breast cancer).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Perimeter Medical Imaging Ai, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.